FDA Grants Breakthrough Designation to VT Ablation System
The pulsed field ablation technology for ventricular tachycardia has been granted FDA Breakthrough Device Designation and accepted into the TAP pilot program.
Category: Catheters and Guidewires
Must-Read Insights
Staff's Top Picks
FDA Greenlights Drug-Coated Balloon for In-Stent Restenosis
The FDA approves Boston Scientific Corporation’s AGENT Drug-Coated Balloon for treating coronary in-stent restenosis, marking the first drug-coated coronary balloon approval in the United States.
Shape-shifting Robotic Catheter Shows Promise for Safer Heart Surgery
The device, designed by a team of physicians and engineers at Boston University, possesses shape-shifting capabilities that allow it to be maneuvered through complex anatomy while maintaining enough stability to accomplish surgical objectives within the heart.
Read More
Atrial Fibrillation Ablation Lowers Death Rates in Heart Failure Patients
Atrial fibrillation ablation is associated with lower rates of death, urgent heart transplantation, or left ventricular assist device implantation compared with medical therapy in patients with end-stage heart failure.
Read More
First Trisol Transcatheter Tricuspid Valve Implantations Performed in US
The heart teams at the Piedmont Heart Institute and the University of Virginia Health System successfully performed the first two implantations in the US as part of an FDA-approved early feasibility study.
Read More
Comparing Balloon-Expandable and Self-Expanding Valves in Transcatheter Aortic Valve Replacement: Which Offers Superior Outcomes?
A recent study delves into the safety and efficacy of using Balloon-Expandable Valves (BEV) versus Self-Expanding Valves (SEV) in transcatheter aortic valve replacement (TAVR) for high-risk patients. Findings reveal significant differences in mortality rates and outcomes, shedding light on the optimal valve choice for improved patient outcomes.
Read MoreAdvancing Heart Failure Treatment: Long-term Benefits of Transcatheter Mitral Valve Repair
A 5-year follow-up study reveals the remarkable effectiveness of transcatheter edge-to-edge repair in treating secondary mitral regurgitation. Patients who underwent this minimally invasive procedure experienced lower rates of heart failure hospitalizations and improved survival compared to those receiving medical therapy alone.
Read MoreThe Transapical Transcatheter Revolution: A New Hope for High-Risk Patients
The Transapical Transcatheter Mitral Valve Repair System: A Game Changer In the realm of cardiac interventions, the transapical transcatheter mitral valve repair system has emerged as a beacon of hope for high-risk patients....
Read MoreEvaluating Cardiac Damage Post-TAVR: Insights for Cardiologists and Prognosis
A recent analysis highlights the importance of evaluating cardiac damage after transcatheter aortic valve replacement (TAVR). The study emphasizes the need to understand the evolution of cardiac damage post-TAVR and its impact on long-term prognosis. By assessing cardiac damage within 30 days of TAVR, cardiologists can gain valuable insights for better patient management and improved outcomes.
Read More
Transcatheter Mitral Valve Repair Offers Hope for Heart Failure Patients with Malnutrition
A recent analysis of the COAPT trial demonstrates that transcatheter edge-to-edge mitral valve repair provides substantial benefits for heart failure patients with severe secondary mitral regurgitation, regardless of their nutritional status.
Read MorePulmonary Artery Catheter Use in Cardiac Intensive Care Units: Impact on Mortality Revealed
A registry analysis of contemporary cardiac intensive care units sheds light on the use and impact of pulmonary artery catheters.
Read More